Profile
Robert Lutz
Ph.D.
Bio
Dr. Lutz is a consultant/advisor to biotech and pharma with more than 30 years of experience with a significant focus on the development of antibody-drug conjugates (ADCs). He currently serves as Chief Scientific Officer of Iksuda Therapeutics and is a board member and Chief Development Officer of Synthis Therapeutics. Prior to his consulting practice, Dr. Lutz was Vice President of translational research and development at ImmunoGen, where he was responsible for the advancement of multiple ADC programs, including KADCYLA® (ado-trastuzumab emtansine), the first ADC to be approved for solid tumor indications, and ELAHERE® (mirvetuximab soravtansine). Dr. Lutz earned a Ph.D. in biochemistry from Brandeis University and a B.S. in biochemistry from the University of New Hampshire.